Take a trial of UK to unlock this pageFind out more


CRX 156.5p 0.0  0.0%
3:39pm 3.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the six months ended 30 June 2016, Cyprotex plc revenues increased 26% to L8.7M. Net income totaled L3M vs. loss of L364K. Revenues reflect North America segment increase of 33% to L4.2M, Rest of Europe segment increase of 42% to L2.4M. Net Income reflects Movement in Loan Note derivative value increase from L0K to L2M (income), Income from deposits increase of 54% to L14K (income). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Cyprotex
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
N+1 Singer Jens Lindqvist Sheena Berry ,

Profile Summary

Cyprotex PLC is a holding company. The Company and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. Its in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. It operates mainly in North America, Mainland Europe and the United Kingdom. It serves pharmaceutical, biotech, cosmetics, personal care, household products, chemical, agrochemical and tobacco markets. Its subsidiaries include Cyprotex Discovery Limited and Cyprotex US, LLC.

Directors: Anthony Baxter (CEO) 55, John Dootson (CFO) 53, Mark Warburton (SEC) , Ian Johnson (NEC) 63, Ralph Harris (NED) 72, Christopher Mills (NED) 63,

No. of Employees: 121 No. of Shareholders: n/a

Last Annual December 31st, 2015
Last Interim June 30th, 2016
Incorporated October 25, 2001
Public Since February 15, 2002
Shares in Issue 22,509,042
Free Float 12.0m (53.4%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

CRX Share Price Performance CRXQuote
0.0  0.0%
Traded 3:39pm · Minimum 15 min delayed · NMS: 3.00k

Latest CRX News Announcements (delayed)

Upcoming CRX Events

Recent ↓
Wednesday 26th October, 2016
Evotec AG Announces Its Intent To Acquire Cyprotex PLC M&A Call
Tuesday 2nd August, 2016
Half Year 2016 Cyprotex PLC Earnings Release
Friday 24th July, 2015 (estimate)
Cyprotex PLC Annual Shareholders Meeting
Monday 28th July, 2014
Cyprotex PLC Reverse Split For CRX.L
Thursday 24th July, 2014
Cyprotex PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy CRX

Access CRX Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis